scholarly journals Metabolic and Endocrine Comorbidities in Hidradenitis Suppurativa: A Nationwide Study

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A21-A21
Author(s):  
Ehizogie Edigin ◽  
Precious O Eseaton ◽  
Hafeez Shaka ◽  
Iriagbonse Asemota ◽  
Emmanuel Akuna ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Hidradenitis Suppurativa ◽  
Interdisciplinary Approach ◽  
The United States ◽  
Acne Inversa ◽  
Inpatient Hospitalization ◽  
Chi Square ◽  
The Metabolic Syndrome

Abstract Introduction: Hidradenitis suppurativa (HS) or acne inversa is a chronic, inflammatory, recurrent, debilitating skin disease. There have been studies linking HS to metabolic syndrome [1]. However, there is a scarcity of studies on metabolic and endocrine co-morbidities of hospitalized HS patients. This study aims to compare the prevalence of metabolic and endocrine co-morbidities in hospitalized HS patients to hospitalized non-HS patients. Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. NIS is the largest inpatient hospitalization database in the United States. The NIS was searched for hospitalizations for adult patients aged 18 years or above with a principal or secondary diagnosis of HS and those without any diagnosis of HS. Chi-square test was used to compare the prevalence of common metabolic and endocrine comorbidities between HS and non-HS hospitalized patients. Co-morbidities were obtained from secondary diagnoses. We used ICD-10 codes to obtain HS hospitalizations and co-morbidities. STATA, version 16 was used for analysis. Results: There were over 71 million discharges in the combined 2016 and 2017 NIS database. Out of which, 40,275 hospitalizations had a diagnosis of HS. HS hospitalizations had higher prevalence of type 2 diabetes (33.1% vs 24.5%, p<0.0001), type 1 diabetes mellitus (1.9% vs 0.9%, p<0.0001), obesity (35.8% vs 14.3%, p<0.0001), lower prevalence of dyslipidemia (21.3% vs 31.8%, p<0.0001), hypothyroidism (6.3% vs 12.0%, p<0.0001) and similar prevalence of hyperthyroidism (0.4% vs 0.5%, p=0.2373) compared to non-HS hospitalizations Conclusion: Hospitalized HS patients have a higher prevalence of type 1 & 2 diabetes mellitus and obesity compared to hospitalized non-HS patients. An interdisciplinary approach involving the endocrinologist, dermatologist, and hospitalist may be needed to optimally manage these co-morbidities in hospitalized HS patients. References 1. Ergun T. Hidradenitis suppurativa and the metabolic syndrome. Clin Dermatol. 2018;36(1):41–47. doi:10.1016/j.clindermatol.2017.09.007

1631-P: Age at Menarche and Its Association with the Metabolic Syndrome in Type 1 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1631-P
Author(s):  
JINGHUI JU ◽  
DEBRA RUBINSTEIN ◽  
SAMAR R. EL KHOUDARY ◽  
TREVOR J. ORCHARD ◽  
TINA COSTACOU
Keyword(s):  
Metabolic Syndrome ◽  
Type 1 Diabetes ◽  
Age At Menarche ◽  
The Metabolic Syndrome

scholarly journals C-Peptide as a Therapy for Type 1 Diabetes Mellitus

Biomedicines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 270
Author(s):  
Rachel L. Washburn ◽  
Karl Mueller ◽  
Gurvinder Kaur ◽  
Tanir Moreno ◽  
Naima Moustaid-Moussa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vascular Complications ◽  
The United States ◽  
Genetically Engineered ◽  
Therapeutic Effects ◽  
Pancreatic Islet Transplantation ◽  
C Peptide ◽  
Increased Risk

Diabetes mellitus (DM) is a complex metabolic disease affecting one-third of the United States population. It is characterized by hyperglycemia, where the hormone insulin is either not produced sufficiently or where there is a resistance to insulin. Patients with Type 1 DM (T1DM), in which the insulin-producing beta cells are destroyed by autoimmune mechanisms, have a significantly increased risk of developing life-threatening cardiovascular complications, even when exogenous insulin is administered. In fact, due to various factors such as limited blood glucose measurements and timing of insulin administration, only 37% of T1DM adults achieve normoglycemia. Furthermore, T1DM patients do not produce C-peptide, a cleavage product from insulin processing. C-peptide has potential therapeutic effects in vitro and in vivo on many complications of T1DM, such as peripheral neuropathy, atherosclerosis, and inflammation. Thus, delivery of C-peptide in conjunction with insulin through a pump, pancreatic islet transplantation, or genetically engineered Sertoli cells (an immune privileged cell type) may ameliorate many of the cardiovascular and vascular complications afflicting T1DM patients.

key genetic factors in the metabolic syndrome predisposition which may be a therapeutic options by gene therapy

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Metabolic Syndrome ◽  
Noncoding Rna ◽  
Insulin Signalling ◽  
Therapeutic Option ◽  
Apoe Genotype ◽  
The United States ◽  
Acid Oxidation ◽  
Therapeutic Effects ◽  
Coding Region ◽  
The Metabolic Syndrome

Metabolic syndrome affects 24–42 percent of individuals over the age of 50 in the United States. Dietary treatments tailored to the APOE genotype may help patients with MeS. Both mitotic and meiotic epigenetics are heritable. SREBP 1 and 2 genes overexpress in response to low cholesterol, statins, and insulin tolerance, resulting in decreased fatty acid oxidation, insulin signalling, and HDL-c levels. FTO is a key gene in the metabolic syndrome predisposition which may be a therapeutic option. MicroRNA repression of the VEGF 62 reference gene is prevented by the LncRNA MIAT/miR-150-5p complex. MEG3, a maternally expressed three-letter noncoding RNA, has been related to endothelial cell angiogenesis. Phosphorylation of p38 and JNK improved in the absence of (SRA) lncRNAs, resulting in decreased insulin signaling.Mipomersen is a 20-mer oligonucleotide that binds to the APOB mRNA's coding region. Volanersorsen has finished phase II and III clinical trials, making it the first APOC3 ASO to do so. ASO targeting APOB3 based on next-generation ligands is also in the early stages of research. Angptl3 is another successful genome editing target. Given the role of ANGPTL3 in TRL metabolism, Dr. David Seres suggests that this editing may have additional or synergistic therapeutic effects. He claims that defects in the LDLR gene cause the most common genetic form of hypercholesterolemia, FH.

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017 ◽  
Vol 36 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Christian Labenz ◽  
Vera Prenosil ◽  
Sandra Koch ◽  
Yvonne Huber ◽  
Jens U. Marquardt ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Hepatocellular Carcinoma ◽  
Metabolic Syndrome ◽  
Group Performance ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
The Metabolic Syndrome ◽  
The Impact

Background/Aim: Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. Methods: Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. Results: The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS. Multivariate analysis showed that Eastern Cooperative Oncology Group Performance Status ≥1 (hazards ratio [HR] 2.03), presence of macrovascular invasion (HR 1.71), Child-Pugh score B/C (HR 2.19), tumor grading G3 (HR 2.17), no prior HCC treatment (HR 2.34), and the presence of 2 or more out of 5 individual components of the MS (HR 0.65) were independent prognostic factors regarding the median OS. Conclusions: Our investigations do not confirm a negative prognostic role of individual components of the MS or the MS itself for patients with advanced HCC treated with sorafenib.

Sign in / Sign up

Export Citation Format

Share Document